An indication marks the headquarters of Moderna Therapeutics, which is creating a vaccine in opposition to the coronavirus illness (COVID-19), in Cambridge, Massachusetts, Could 18, 2020.
Brian Snyder | Reuters
Moderna’s inventory fell 8% on Thursday after a report mentioned the biotech firm’s late-stage trial for a possible coronavirus vaccine can be delayed.
The corporate, which is working with the Nationwide Institutes of Well being, was anticipated to start a part three trial for its vaccine candidate later this month, pending the outcomes from its mid-stage trial.
Nonetheless, the corporate is making modifications to the trial plan, which has pushed again the anticipated begin date, according to health-care publication STAT News, citing an investigator.
This can be a creating story. Please examine again for updates.